Adicet Bio (LTS:0HX7) Change In Payables And Accrued Expense : $-0.33 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Change In Payables And Accrued Expense?

Adicet Bio's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-1.98 Mil. It means Adicet Bio's Accounts Payable & Accrued Expense declined by $1.98 Mil from Dec. 2023 to Mar. 2024 .

Adicet Bio's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-0.93 Mil. It means Adicet Bio's Accounts Payable & Accrued Expense declined by $0.93 Mil from Dec. 2022 to Dec. 2023 .

Adicet Bio Change In Payables And Accrued Expense Historical Data

The historical data trend for Adicet Bio's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Change In Payables And Accrued Expense Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.17

-0.03

1.98

7.54

-0.93

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-2.58	0.98	1.42	-0.75	-1.98

Adicet Bio Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.33 Mil.

Adicet Bio Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (LTS:0HX7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (LTS:0HX7) Headlines

No Headlines